{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-042483","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-09-14T12:00:18+00:00","discovered_at":"2026-09-14T12:05:00.759607+00:00","generated_at":"2026-09-14T12:05:40.715182+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir announces preclinical osteosarcoma data: Telomir-Zn inhibits growth in human and canine cell lines","bullets":["Ohio State study: Telomir-Zn inhibited growth in HOS (human), D17 (canine), and Abrams (canine) osteosarcoma cell lines at similar low drug concentrations.","Company assessing potential in vivo canine osteosarcoma efficacy study with Ohio State; TNBC Phase 1/2 enrollment advancing toward site initiation.","Lead investigator Shay Bracha, DVM, DACVIM (Oncology); findings support translational development in both veterinary and human osteosarcoma.","TNBC program remains immediate focus under active FDA-cleared IND; osteosarcoma is a parallel Track 2 development pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-042483","json":"https://secwatch.observer/filing/0001493152-26-042483.json","markdown":"https://secwatch.observer/filing/0001493152-26-042483.md","text":"https://secwatch.observer/filing/0001493152-26-042483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/0001493152-26-042483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T12:05:40.715182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}